![Luke Walker](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Luke Walker
Chief Tech/Sci/R&D Officer at HARPOON THERAPEUTICS, INC.
Net worth: 296 447 $ as of 2024-06-29
Profile
Luke N.
Walker is an Independent Director at Zentalis Pharmaceuticals, Inc. since 2024 and the Chief Medical Officer at Harpoon Therapeutics, Inc. since 2022.
Previously, Dr. Walker held positions as Vice President-Clinical Development at Seagen Inc. and Cascadian Therapeutics LLC.
Dr. Walker completed undergraduate, graduate, and doctorate degrees at the University of Oklahoma.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2024-05-23 | 72,481 ( 0.10% ) | 296 447 $ | 2024-06-29 |
Luke Walker active positions
Companies | Position | Start |
---|---|---|
HARPOON THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2022-10-02 |
ZENTALIS PHARMACEUTICALS, INC. | Director/Board Member | 2024-05-28 |
Former positions of Luke Walker
Companies | Position | End |
---|---|---|
CASCADIAN THERAPEUTICS INC (USA) | Chief Tech/Sci/R&D Officer | 2018-03-08 |
SEAGEN INC. | Corporate Officer/Principal | - |
Training of Luke Walker
University of Oklahoma | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
ZENTALIS PHARMACEUTICALS, INC. | Health Technology |
Private companies | 3 |
---|---|
Cascadian Therapeutics LLC
![]() Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC was a clinical-stage biopharmaceutical company, which focused on the development of therapeutic products for the treatment of cancer. Its product ONT-380, was an orally active and selective small-molecule HER2 inhibitor. The firm also developed preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on August 23, 1985 and was headquartered in Bothell, WA. | Health Technology |
Harpoon Therapeutics, Inc.
![]() Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA. | Health Technology |
Seagen Inc.
![]() Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
- Stock Market
- Insiders
- Luke Walker